Olli Kallioniemi

List of Publications by Year in Descending Order

376 papers	44,694 citations	99 h-index	206 g-index
460 ext. papers	48,888 ext. citations	8.5 avg, IF	6.54 L-index

#	Paper	IF	Citations
376	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. *Cancer Research Communications*, **2022**, 2, 172-181		0
375	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.. *Nature Communications*, **2022**, 13, 1691	17.4	0
374	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. *Translational Oncology*, **2021**, 15, 101290	4.9	0
373	Implementing a functional precision medicine tumor board for acute myeloid leukemia. *Cancer Discovery*, **2021**,	24.4	8
372	Multiomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health. *Cell Systems*, **2021**,	10.6	3
371	Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish Adults. *Journal of Nutrition*, **2021**, 151, 281-292	4.1	4
370	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells. *Translational Oncology*, **2021**, 14, 101027	4.9	2
369	High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. *Journal of Pathology: Clinical Research*, **2021** , 7, 482-494	5.3	0
368	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. *Npj Precision Oncology*, **2021**, 5, 71	9.8	0
367	The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia. *American Journal of Hematology*, **2021**, 96, 580-588	7.1	2
366	The Porto European Cancer Research Summit 2021. *Molecular Oncology*, **2021**, 15, 2507-2543	7.9	1
365	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. *Scientific Reports*, **2021**, 11, 23565	4.9	0
364	Building an international consortium for tracking coronavirus health status. *Nature Medicine*, **2020**, 26, 1161-1165	50.5	16
363	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. *Bioinformatics*, **2020**, 36, 3602-3604	7.2	23
362	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. *Cell Death and Disease*, **2020**, 11, 790	9.8	17
361	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. *Leukemia*, **2020**, 34, 2780-2784	10.7	2
360	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. *Haematologica*, **2020**, 105, 1527-1538	6.6	8

359	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. *Blood Advances*, **2020**, 4, 274-286	7.8	18
358	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. *Leukemia*, **2019**, 33, 2548-2553	10.7	8
357	Individual and stable autoantibody repertoires in healthy individuals. *Autoimmunity*, **2019**, 52, 1-11	3	30
356	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. *International Journal of Cancer*, **2019**, 144, 1356-1366	7.5	15
355	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. *Prostate*, **2019**, 79, 1505-1513	4.2	14
354	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 4641-4641	2.2	1
353	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. *British Journal of Cancer*, **2019**, 120, 435-443	8.7	14
352	Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer. *Personalized Medicine*, **2019**, 16, 51-65	2.2	12
351	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. *Leukemia*, **2019**, 33, 1570-1582	10.7	26
350	Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. *Journal of Pathology: Clinical Research*, **2019**, 5, 63-78	5.3	11
349	Anagrelide for Gastrointestinal Stromal Tumor. *Clinical Cancer Research*, **2019**, 25, 1676-1687	12.9	9
348	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. *Haematologica*, **2019**, 104, 338-346	6.6	26
347	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours. *Journal of Pathology*, **2018**, 245, 101-113	9.4	8
346	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 3002-3005	1.9	
345	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 2220-2230	5.6	8
344	ITGB1-dependent upregulation of Caveolin-1 switches TGF signalling from tumour-suppressive to oncogenic in prostate cancer. *Scientific Reports*, **2018**, 8, 2338	4.9	15
343	PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. *Haematologica*, **2018**, 103, 1908-1914	6.6	49
342	Association of tamoxifen resistance and lipid reprogramming in breast cancer. *BMC Cancer*, **2018**, 18, 850	4.8	62

341	Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. *Molecular Oncology*, **2018**, 12, 1639-1655	7.9	30
340	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. *Leukemia*, **2018**, 32, 1643-1656	10.7	42
339	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. *Blood*, **2018**, 132, 2763-2763	2.2	1
338	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. *Blood*, **2018**, 132, 264-264	2.2	1
337	Predictive Response Biomarkers for BET Inhibitors in AML. *Blood*, **2018**, 132, 2749-2749	2.2	0
336	Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. *Blood*, **2018**, 132, 2774-2774	2.2	
335	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. *Clinical Cancer Research*, **2018**, 24, 794-806	12.9	116
334	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. *Leukemia*, **2018**, 32, 774-787	10.7	56
333	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. *Molecular Cancer Therapeutics*, **2018**, 17, 2060-2071	6.1	17
332	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. *European Urology*, **2017**, 71, 319-327	10.2	50
331	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. *Gynecologic Oncology*, **2017**, 144, 621-630	4.9	22
330	associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. *Journal of Pathology: Clinical Research*, **2017**, 3, 123-138	5.3	10
329	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. *Blood*, **2017**, 130, 789-802	2.2	63
328	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. *Molecular Oncology*, **2017**, 11, 1156-1171	7.9	11
327	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. *Cell Reports*, **2017**, 18, 673-684	10.6	30
326	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. *Breast Cancer: Targets and Therapy*, **2017**, 9, 185-198	3.9	17
325	Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. *Scientific Reports*, **2017**, 7, 15580	4.9	91
324	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. *Leukemia*, **2017**, 31, 1048-1058	10.7	8

323	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. *Leukemia*, **2017**, 31, 1187-1195	10.7	35
322	KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. *European Journal of Pharmaceutical Sciences*, **2017**, 98, 30-39	5.1	41
321	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. *Leukemia*, **2017**, 31, 301-309	10.7	41
320	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. *Leukemia*, **2017**, 31, 51-57	10.7	24
319	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. *Blood Advances*, **2017**, 1, 2257-2268	7.8	17
318	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. *Theranostics*, **2017**, 7, 3824-3841	12.1	116
317	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. *BMC Genomics*, **2017**, 18, 629	4.5	29
316	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. *Blood*, **2017**, 130, 854-854	2.2	1
315	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. *Oncotarget*, **2017**, 8, 22606-22615	3.3	8
314	Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. *European Urology*, **2016**, 69, 1120-8	10.2	43
313	Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. *PLoS Pathogens*, **2016**, 12, e1005424	7.6	24
312	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. *Journal of Molecular Biochemistry*, **2016**, 5, 12-22	0.2	7
311	Intrinsic resistance to PIM kinase inhibition in AML through p38-mediated feedback activation of mTOR signaling. *Oncotarget*, **2016**, 7, 37407-37419	3.3	14
310	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. *Journal of Clinical Oncology*, **2016**, 34, 604-604	2.2	
309	Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. *Blood*, **2016**, 128, 1897-1897	2.2	
308	A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. *Oncotarget*, **2016**, 7, 28510-22	3.3	12
307	Consistency in drug response profiling. *Nature*, **2016**, 540, E5-E6	50.4	53
306	Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. *BMC Cancer*, **2016**, 16, 378	4.8	9

305	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. *Bioinformatics*, **2016**, 32, i455-i463	7.2	57
304	The impact of low-frequency and rare variants on lipid levels. *Nature Genetics*, **2015**, 47, 589-97	36.3	229
303	MicroRNA-135b regulates ERAR and HIF1AN and affects breast and prostate cancer cell growth. *Molecular Oncology*, **2015**, 9, 1287-300	7.9	31
302	Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. *International Journal of Cancer*, **2015**, 136, 2535-45	7.5	7
301	Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?. *EMBO Molecular Medicine*, **2015**, 7, 994-5	12	3
300	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. *Blood Cancer Journal*, **2015**, 5, e309	7	13
299	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. *Bioinformatics*, **2015**, 31, 3815-21	7.2	16
298	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data. *Molecular and Cellular Proteomics*, **2015**, 14, 3274-83	7.6	12
297	miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen. *European Urology*, **2015**, 68, 581-8	10.2	30
296	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. *Nature*, **2015**, 519, 102-5	50.4	168
295	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. *Blood*, **2015**, 126, 2462-2462	2.2	
294	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. *Blood*, **2015**, 126, 867-867	2.2	
293	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Scientific Reports*, **2014**, 4, 5193	4.9	150
292	Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3689-96	5.9	30
291	Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. *Oncogene*, **2014**, 33, 3538-49	9.2	28
290	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. *Molecular Oncology*, **2014**, 8, 93-104	7.9	127
289	Break-induced replication repair of damaged forks induces genomic duplications in human cells. *Science*, **2014**, 343, 88-91	33.3	308
288	Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization. *Journal of Chemical Information and Modeling*, **2014**, 54, 2347-59	6.1	67

287	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. *Leukemia*, **2014**, 28, 1738-42	10.7	75
286	A community effort to assess and improve drug sensitivity prediction algorithms. *Nature Biotechnology*, **2014**, 32, 1202-12	44.5	447
285	Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. *PLoS ONE*, **2014**, 9, e96767	3.7	45
284	Genetic Instability of Influenza pH1N1 Viruses. *Genome Announcements*, **2014**, 2,		5
283	A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. *International Journal of Cancer*, **2014**, 135, 2077-84	7.5	15
282	Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. *Cell Death and Disease*, **2014**, 5, e1043	9.8	20
281	Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. *Bioinformatics*, **2014**, 30, i497-504	7.2	28
280	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2367-2367	2.2	1
279	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. *Blood*, **2014**, 124, 917-917	2.2	
278	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. *Blood*, **2014**, 124, 3505-3505	2.2	
277	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. *Blood*, **2014**, 124, 2203-2203	2.2	
276	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. *Blood*, **2014**, 124, 2046-2046	2.2	
275	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. *Blood*, **2014**, 124, 1022-1022	2.2	
274	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. *Blood*, **2014**, 124, 2163-2163	2.2	
273	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. *Blood*, **2014**, 124, 3139-3139	2.2	
272	Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. *Carcinogenesis*, **2013**, 34, 2000-9	4.6	4
271	Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK/IKK. *Oncogene*, **2013**, 32, 4892-902	9.2	95
270	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. *Molecular Oncology*, **2013**, 7, 392-401	7.9	56

269	Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. *Cancer Discovery*, **2013**, 3, 1416-29	24.4	247
268	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. *Blood*, **2013**, 121, 4541-50	10.2	204
267	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. *Blood Cancer Journal*, **2013**, 3, e168	7	48
266	ARLTS1 and prostate cancer risk--analysis of expression and regulation. *PLoS ONE*, **2013**, 8, e72040	3.7	8
265	Plasticity of blood- and lymphatic endothelial cells and marker identification. *PLoS ONE*, **2013**, 8, e74293	3.7	14
264	High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells. *PLoS ONE*, **2013**, 8, e77232	3.7	121
263	Novel Activating STAT5B Mutations As Drivers Of T-ALL. *Blood*, **2013**, 122, 3863-3863	2.2	1
262	Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. *PLoS ONE*, **2013**, 8, e60930	3.7	36
261	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. *Oncotarget*, **2013**, 4, 48-63	3.3	74
260	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. *Blood*, **2013**, 122, 1668-1668	2.2	
259	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. *Blood*, **2013**, 122, 3828-3828	2.2	
258	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. *Blood*, **2013**, 122, 482-482	2.2	
257	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. *Blood*, **2013**, 122, 2719-2719	2.2	
256	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. *Oncogene*, **2012**, 31, 2090-100	9.2	99
255	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. *Breast Cancer Research*, **2012**, 14, R113	8.3	36
254	MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. *Neoplasia*, **2012**, 14, 868-79	6.4	117
253	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. *Oncogene*, **2012**, 31, 3444-56	9.2	96
252	Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. *BMC Bioinformatics*, **2012**, 13, 112	3.6	16

251	Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. *Journal of Proteome Research*, **2012**, 11, 850-60	5.6	58
250	Identification of microRNAs inhibiting TGF-□nduced IL-11 production in bone metastatic breast cancer cells. *PLoS ONE*, **2012**, 7, e37361	3.7	60
249	High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. *PLoS ONE*, **2012**, 7, e39801	3.7	40
248	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population **2012**,		2
247	15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. *Journal of Pathology*, **2012**, 226, 674-86	9.4	25
246	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. *Prostate*, **2012**, 72, 789-802	4.2	21
245	Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. *Molecular Cancer Research*, **2012**, 10, 597-604	6.6	30
244	A functional genetic screen reveals new regulators of □1-integrin activity. *Journal of Cell Science*, **2012**, 125, 649-61	5.3	35
243	c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells. *Molecular and Cellular Biology*, **2012**, 32, 3513-26	4.8	50
242	HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. *Oncogene*, **2012**, 31, 1299-310	9.2	20
241	Somatic STAT3 mutations in large granular lymphocytic leukemia. *New England Journal of Medicine*, **2012**, 366, 1905-13	59.2	535
240	Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. *Oncogene*, **2012**, 31, 2075-89	9.2	34
239	Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. *Oncogene*, **2012**, 31, 3597-606	9.2	37
238	Interaction with ErbB4 promotes hypoxia-inducible factor-1□signaling. *Journal of Biological Chemistry*, **2012**, 287, 9659-9671	5.4	36
237	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. *British Journal of Cancer*, **2012**, 106, 99-106	8.7	114
236	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2 **2012**,		2
235	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. *Blood*, **2012**, 120, 871-871	2.2	2
234	Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms. *PLoS ONE*, **2012**, 7, e48745	3.7	53

233	Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. *PLoS ONE*, **2012**, 7, e50819	3.7	7
232	Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. *PLoS ONE*, **2012**, 7, e51470	3.7	23
231	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. *Blood*, **2012**, 120, 288-288	2.2	1
230	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. *Blood*, **2012**, 120, 1302-1302	2.2	
229	Identification of fusion genes in breast cancer by paired-end RNA-sequencing. *Genome Biology*, **2011**, 12, R6	18.3	227
228	Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. *Genome Medicine*, **2011**, 3, 63	14.4	9
227	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. *American Journal of Pathology*, **2011**, 178, 525-36	5.8	80
226	Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. *Nature Reviews Clinical Oncology*, **2011**, 8, 142-50	19.4	230
225	Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. *PLoS ONE*, **2011**, 6, e26595	3.7	7
224	SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. *American Journal of Surgical Pathology*, **2011**, 35, 937-48	6.7	183
223	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. *European Urology*, **2011**, 59, 671-81	10.2	355
222	Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. *Breast Cancer Research and Treatment*, **2011**, 125, 421-30	4.4	172
221	Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. *BioData Mining*, **2011**, 4, 5	4.3	5
220	A cell spot microarray method for production of high density siRNA transfection microarrays. *BMC Genomics*, **2011**, 12, 162	4.5	48
219	Androgen regulation of micro-RNAs in prostate cancer. *Prostate*, **2011**, 71, 604-14	4.2	129
218	The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. *Genes Chromosomes and Cancer*, **2011**, 50, 499-509	5	39
217	SHARPIN is an endogenous inhibitor of β1-integrin activation. *Nature Cell Biology*, **2011**, 13, 1315-24	23.4	159
216	Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. *Molecular and Cellular Proteomics*, **2011**, 10, M110.005322	7.6	54

215	KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers. *Cancer Discovery*, **2011**, 1, 12-3	24.4	3
214	Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. *Cancer Research*, **2011**, 71, 3236-45	10.1	363
213	Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. *Cancer Research*, **2011**, 71, 1956-67	10.1	206
212	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. *EMBO Journal*, **2011**, 30, 3962-76	13	259
211	Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells **2011**,		3
210	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. *PLoS ONE*, **2011**, 6, e16915	3.7	258
209	GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. *PLoS ONE*, **2011**, 6, e17259	3.7	24
208	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. *Oncotarget*, **2011**, 2, 1176-90	3.3	63
207	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. *Blood*, **2011**, 118, 2487-2487	2.2	
206	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. *Blood*, **2011**, 118, 936-936	2.2	
205	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
204	A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. *PLoS ONE*, **2010**, 5, e10431	3.7	247
203	Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome. *PLoS ONE*, **2010**, 5, e15068	3.7	32
202	Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. *Molecular Cancer Therapeutics*, **2010**, 9, 3175-85	6.1	67
201	Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. *Cancer Research*, **2010**, 70, 7851-61	10.1	39
200	Cancer genomes. *Clinical Chemistry*, **2010**, 56, 1660-4	5.5	5
199	FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. *Cancer Research*, **2010**, 70, 6735-45	10.1	203
198	Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. *Epigenomics*, **2010**, 2, 683-9	4.4	3

197	Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. *Neoplasia*, **2010**, 12, 877-88	6.4	37
196	A decade of cancer gene profiling: from molecular portraits to molecular function. *Methods in Molecular Biology*, **2010**, 576, 61-87	1.4	9
195	Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. *Experimental Cell Research*, **2010**, 316, 1610-24	4.2	26
194	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. *Genes Chromosomes and Cancer*, **2010**, 49, 1062-9	5	161
193	Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. *Clinical Cancer Research*, **2009**, 15, 6570-81	12.9	30
192	Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. *Carcinogenesis*, **2009**, 30, 1032-40	4.6	41
191	High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. *Clinical Cancer Research*, **2009**, 15, 6070-8	12.9	148
190	CIP2A is associated with human breast cancer aggressivity. *Clinical Cancer Research*, **2009**, 15, 5092-100	12.9	190
189	Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations. *BMC Bioinformatics*, **2009**, 10 Suppl 1, S24	3.6	32
188	Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. *Journal of Computer-Aided Molecular Design*, **2009**, 23, 227-39	4.2	9
187	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. *BMC Medical Genomics*, **2009**, 2, 26	3.7	7
186	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. *Oncogene*, **2009**, 28, 3926-36	9.2	186
185	Critical comparison of virtual screening methods against the MUV data set. *Journal of Chemical Information and Modeling*, **2009**, 49, 2168-78	6.1	38
184	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. *European Journal of Cancer*, **2009**, 45, 1510-7	7.5	64
183	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *British Journal of Cancer*, **2008**, 98, 1457-66	8.7	358
182	Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. *Genome Biology*, **2008**, 9, R139	18.3	215
181	Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. *Cell*, **2008**, 133, 537-48	56.2	150
180	P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells. *Cancer Treatment Reviews*, **2008**, 34, 22	14.4	2

179	Integrin trafficking regulated by Rab21 is necessary for cytokinesis. *Developmental Cell*, **2008**, 15, 371-385	10.2	153
178	Role of ErbB4 in breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **2008**, 13, 259-68	2.4	102
177	Functional evidence implicating S100P in prostate cancer progression. *International Journal of Cancer*, **2008**, 123, 330-339	7.5	49
176	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. *International Journal of Cancer*, **2008**, 123, 2774-81	7.5	57
175	Cancer genome analysis: a landscape seen from many angles. *Drug Discovery Today Disease Mechanisms*, **2007**, 4, 269-276		
174	Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. *Oncogene*, **2007**, 26, 3846-56	9.2	130
173	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. *Nature Methods*, **2007**, 4, 13-7	21.6	207
172	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. *BMC Genomics*, **2007**, 8, 84	4.5	36
171	Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. *Carcinogenesis*, **2007**, 28, 1040-5	4.6	16
170	Integrated breast cancer genomics. *Cancer Cell*, **2006**, 10, 453-4	24.3	3
169	Human Protein Atlas charts a diverse terrain. *Trends in Biotechnology*, **2006**, 24, 195-7	15.1	12
168	Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. *Cancer Research*, **2006**, 66, 743-7	10.1	51
167	TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. *Cancer Research*, **2006**, 66, 10242-6	10.1	188
166	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. *European Journal of Human Genetics*, **2006**, 14, 167-72	5.3	36
165	Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. *Oncogene*, **2006**, 25, 6997-7008	9.2	85
164	Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. *Analytical Cellular Pathology*, **2006**, 28, 315-26	3.4	48
163	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. *Breast Cancer Research*, **2005**, 7, 1	8.3	1
162	Application of Microarray Technologies for Translational Genomics **2005**, 361-374		

161	Functional genomics and transcriptomics of prostate cancer: promises and limitations. *BJU International*, **2005**, 96 Suppl 2, 10-5	5.6	6
160	Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. *International Journal of Cancer*, **2005**, 113, 575-80	7.5	85
159	Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. *Human Genetics*, **2005**, 116, 43-50	6.3	23
158	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. *Human Genetics*, **2005**, 117, 307-16	6.3	27
157	EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. *Clinical Cancer Research*, **2005**, 11, 6450-8	12.9	76
156	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. *Journal of Medical Genetics*, **2005**, 42, 602-3	5.8	107
155	Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. *Cancer Research*, **2005**, 65, 5588-98	10.1	173
154	NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. *Analytical Cellular Pathology*, **2005**, 27, 169-73	3.4	6
153	Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. *Clinical Cancer Research*, **2004**, 10, 2344-50	12.9	35
152	Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. *Nature Genetics*, **2004**, 36, 979-83	36.3	167
151	Genome-wide scanning for linkage in Finnish breast cancer families. *European Journal of Human Genetics*, **2004**, 12, 98-104	5.3	27
150	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. *Oncogene*, **2004**, 23, 2264-74	9.2	62
149	Medicine: profile of a tumour. *Nature*, **2004**, 428, 379-82	50.4	19
148	CHEK2 1100delC is not a risk factor for male breast cancer population. *International Journal of Cancer*, **2004**, 108, 475-6	7.5	46
147	CHEK2 variant I157T may be associated with increased breast cancer risk. *International Journal of Cancer*, **2004**, 111, 543-7	7.5	114
146	A strategy for identifying putative causes of gene expression variation in human cancers. *Journal of the Franklin Institute*, **2004**, 341, 77-88	4	18
145	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. *Neoplasia*, **2004**, 6, 240-247	6.4	104
144	BRCA2 mutations in 154 finnish male breast cancer patients. *Neoplasia*, **2004**, 6, 541-5	6.4	31

143	Are data from different gene expression microarray platforms comparable?. *Genomics*, **2004**, 83, 1164-8	4.3	162
142	Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps. *Machine Learning*, **2003**, 52, 45-66	4	32
141	Androgen receptor gene alterations in Finnish male breast cancer. *Breast Cancer Research and Treatment*, **2003**, 77, 167-70	4.4	27
140	Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. *Prostate*, **2003**, 57, 280-9	4.2	46
139	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. *Oncogene*, **2003**, 22, 2021-33	9.2	380
138	High frequency of BRAF mutations in nevi. *Nature Genetics*, **2003**, 33, 19-20	36.3	1355
137	RNAi microarray analysis in cultured mammalian cells. *Genome Research*, **2003**, 13, 2341-7	9.7	153
136	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *American Journal of Human Genetics*, **2003**, 72, 1117-30	11	2643
135	Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. *Neoplasia*, **2003**, 5, 397-404	6.4	37
134	BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. *Journal of Medical Genetics*, **2003**, 40, e98	5.8	16
133	Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *Journal of Clinical Oncology*, **2003**, 21, 4586-91	2.2	62
132	New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. *Journal of the National Cancer Institute*, **2003**, 95, 812-8	9.7	50
131	A novel strategy for microarray quality control using Bayesian networks. *Bioinformatics*, **2003**, 19, 2031-8	7.2	41
130	Simulation Toolbox for 3D-FISH Spot-Counting Algorithms. *Real Time Imaging*, **2002**, 8, 203-212		14
129	Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. *Genes Chromosomes and Cancer*, **2002**, 35, 311-7	5	77
128	A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. *Human Genetics*, **2002**, 110, 111-21	6.3	63
127	Androgen receptor CAG polymorphism and prostate cancer risk. *Human Genetics*, **2002**, 111, 166-71	6.3	54
126	Clinical and functional target validation using tissue and cell microarrays. *Current Opinion in Chemical Biology*, **2002**, 6, 97-101	9.7	35

125	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. *Nature Genetics*, **2002**, 30, 181-4	36.3	418
124	Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization. *Journal of Biomedical Optics*, **2002**, 7, 109-22	3.5	15
123	Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. *American Journal of Pathology*, **2002**, 161, 1991-6	5.8	453
122	Expression of Bcl-2 family member Bid in normal and malignant tissues. *Neoplasia*, **2002**, 4, 129-40	6.4	64
121	Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. *American Journal of Human Genetics*, **2002**, 70, 1299-304	11	181
120	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. *American Journal of Human Genetics*, **2002**, 71, 432-8	11	354
119	Genetic changes in familial prostate cancer by comparative genomic hybridization. *Prostate*, **2001**, 46, 233-9	4.2	26
118	Tissue microarrays (TMAs) for high-throughput molecular pathology research. *International Journal of Cancer*, **2001**, 94, 1-5	7.5	197
117	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. *Seminars in Cancer Biology*, **2001**, 11, 395-401	12.7	19
116	Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. *Cancer Causes and Control*, **2001**, 12, 223-30	2.8	36
115	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. *British Journal of Cancer*, **2001**, 84, 116-9	8.7	29
114	Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. *European Journal of Human Genetics*, **2001**, 9, 773-9	5.3	21
113	Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity. *Oncogene*, **2001**, 20, 6881-90	9.2	50
112	Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. *Oncogene*, **2001**, 20, 6718-23	9.2	109
111	RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. *Journal of the National Cancer Institute*, **2001**, 93, 153-154	9.7	1
110	A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. *British Journal of Cancer*, **2001**, 84, 1344-7	8.7	41
109	ANX7, a candidate tumor suppressor gene for prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 4575-80	11.5	113
108	Tissue microarrays for rapid linking of molecular changes to clinical endpoints. *American Journal of Pathology*, **2001**, 159, 2249-56	5.8	471

107	Gene-expression profiles in hereditary breast cancer. *New England Journal of Medicine*, **2001**, 344, 539-48	59.2	1462
106	Biochip technologies in cancer research. *Annals of Medicine*, **2001**, 33, 142-7	1.5	70
105	Tissue microarray technology for high-throughput molecular profiling of cancer. *Human Molecular Genetics*, **2001**, 10, 657-62	5.6	418
104	CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. *Analytical Cellular Pathology*, **2001**, 22, 229-34		53
103	ANX7 as a bio-marker in prostate and breast cancer progression. *Disease Markers*, **2001**, 17, 115-20	3.2	26
102	Tissue microarrays: what will they bring to molecular and anatomic pathology?. *Advances in Anatomic Pathology*, **2001**, 8, 14-20	5.1	119
101	Nationwide cancer family ascertainment using Finnish Cancer Registry data on family names and places of birth for 35,761 prostate cancer patients. *International Journal of Cancer*, **2000**, 88, 307-12	7.5	5
100	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. *European Journal of Human Genetics*, **2000**, 8, 757-63	5.3	64
99	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. *Cancer Genetics and Cytogenetics*, **2000**, 123, 128-32		55
98	Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 9603-8	11.5	133
97	Distance-based reconstruction of tree models for oncogenesis. *Journal of Computational Biology*, **2000**, 7, 789-803	1.7	76
96	Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. *Journal of the National Cancer Institute*, **2000**, 92, 1529-31	9.7	140
95	Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. *Journal of the National Cancer Institute*, **2000**, 92, 1252-9	9.7	231
94	High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. *American Journal of Pathology*, **2000**, 157, 787-94	5.8	216
93	ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER. *Journal of Urology*, **2000**, 164, 1992-1995	2.5	115
92	Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 730-5	5.6	75
91	A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. *Journal of Biological Chemistry*, **1999**, 274, 34283-93	5.4	169
90	Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. *Journal of the National Cancer Institute*, **1999**, 91, 1758-64	9.7	298

89	Molecular cytogenetic analysis of 11 new breast cancer cell lines. *British Journal of Cancer*, **1999**, 81, 1328-34	7	159
88	Inferring tree models for oncogenesis from comparative genome hybridization data. *Journal of Computational Biology*, **1999**, 6, 37-51	1.7	155
87	Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. *Genes Chromosomes and Cancer*, **1999**, 24, 56-61	5	47
86	High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. *American Journal of Pathology*, **1999**, 154, 981-6	5.8	337
85	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 730-735	5.6	67
84	Evidence for a prostate cancer susceptibility locus on the X chromosome. *Nature Genetics*, **1998**, 20, 175-9	36.3	592
83	Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nature Medicine*, **1998**, 4, 844-7	50.5	3329
82	Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. *Cytogenetic and Genome Research*, **1998**, 82, 189-91	1.9	9
81	Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 8703-8	11.5	248
80	Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. *Human Molecular Genetics*, **1997**, 6, 2309-15	5.6	106
79	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science*, **1997**, 277, 965-8	33.3	1340
78	Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. *European Urology*, **1997**, 31, 216-9	10.2	59
77	Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. *British Journal of Cancer*, **1997**, 75, 190-5	8.7	58
76	Genome screening by comparative genomic hybridization. *Trends in Genetics*, **1997**, 13, 405-9	8.5	249
75	Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. *Genes Chromosomes and Cancer*, **1997**, 19, 286-90	5	46
74	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. *Genes Chromosomes and Cancer*, **1997**, 20, 372-6	5	67
73	Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. *Genes Chromosomes and Cancer*, **1997**, 20, 383-91	5	98
72	Quality control of CGH: impact of metaphase chromosomes and the dynamic range of hybridization. *Cytometry*, **1997**, 28, 198-205		48

71	Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. *Science*, **1996**, 274, 1371-4	33.3	635
70	Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. *Cancer Genetics and Cytogenetics*, **1996**, 89, 7-13		43
69	Comparative genomic hybridization gaining in popularity. *Trends in Genetics*, **1996**, 12, 237-238	8.5	4
68	Fiber-FISH: experiences and a refined protocol. *Genetic Analysis, Techniques and Applications*, **1996**, 12, 179-184		30
67	Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. *International Journal of Cancer*, **1996**, 66, 6-10	7.5	9
66	Evaluation of camera requirements for comparative genomic hybridization. *Cytometry*, **1996**, 25, 394-8		4
65	c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. *British Journal of Cancer*, **1996**, 73, 620-3	8.7	24
64	Genetic basis and clonal evolution of human prostate cancer. *Advances in Cancer Research*, **1996**, 68, 225-55	5.9	45
63	Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. *Circulation*, **1996**, 93, 1079-82	16.7	67
62	Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1996**, 56, 57-63	2	17
61	Molecular Cytogenetics of Solid Tumor Progression **1996**, 68-78		1
60	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nature Genetics*, **1995**, 9, 401-6	36.3	1166
59	Mechanically stretched chromosomes as targets for high-resolution FISH mapping. *Genome Research*, **1995**, 5, 13-20	9.7	24
58	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. *Genomics*, **1995**, 26, 134-7	4.3	47
57	Visual mapping by fiber-FISH. *Genomics*, **1995**, 30, 31-6	4.3	70
56	The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2q22. *Cytogenetic and Genome Research*, **1995**, 68, 61-3	1.9	17
55	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **1995**, 12, 213-9	5	182
54	Hardware and software requirements for quantitative analysis of comparative genomic hybridization. *Cytometry*, **1995**, 19, 4-9		76

53	Computer image analysis of comparative genomic hybridization. *Cytometry*, **1995**, 19, 10-26		223
52	Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. *Cancer*, **1994**, 73, 652-8	6.4	94
51	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. *Genes Chromosomes and Cancer*, **1994**, 10, 231-43	5	1065
50	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. *Cytometry*, **1994**, 16, 93-9		105
49	Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. *Cytometry*, **1994**, 16, 250-5		29
48	Physical mapping of chromosome 17 cosmids by fluorescence in situ hybridization and digital image analysis. *Genomics*, **1994**, 20, 125-8	4.3	35
47	Molecular cytogenetics of human breast cancer. *Cold Spring Harbor Symposia on Quantitative Biology*, **1994**, 59, 645-52	3.9	23
46	Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 2156-60	11.5	602
45	Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. *Human Pathology*, **1993**, 24, 1348-53	3.7	10
44	Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. *Journal of Clinical Oncology*, **1993**, 11, 36-43	2.2	101
43	Consensus review of the clinical utility of DNA content cytometry in prostate cancer. *Cytometry*, **1993**, 14, 497-500		107
42	Extrachromosomal gene amplification in acute myeloid leukemia; characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. *Genes Chromosomes and Cancer*, **1993**, 8, 185-9	5	42
41	Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. *Journal of the National Cancer Institute*, **1992**, 84, 1109-14	9.7	319
40	Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. *Journal of the National Cancer Institute*, **1992**, 84, 883-7	9.7	274
39	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 5321-5	11.5	442
38	Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. *Cytogenetic and Genome Research*, **1992**, 60, 190-3	1.9	43
37	Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. *Science*, **1992**, 258, 818-21	33.3	2764
36	Molecular cytogenetics: diagnosis and prognostic assessment. *Current Opinion in Biotechnology*, **1992**, 3, 623-31	11.4	20

35	Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. *British Journal of Cancer*, **1991**, 64, 578-82	8.7	46
34	Cigarette smoking alters sympathoadrenal regulation by decreasing the density of beta 2-adrenoceptors. A study of monitored smoking cessation. *Journal of Cardiovascular Pharmacology*, **1991**, 17, 923-8	3.1	41
33	Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. *International Journal of Cancer*, **1991**, 49, 650-5	7.5	325
32	Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. *Cytometry*, **1991**, 12, 413-21		66
31	Primary undifferentiated small cell carcinoma of the esophagus: clinicopathological and flow cytometric evaluation of eight cases. *Journal of Surgical Oncology*, **1991**, 46, 174-7	2.8	37
30	Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer. *Acta Oncologica*, **1990**, 29, 983-8	3.2	13
29	Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. *British Journal of Cancer*, **1990**, 62, 142-6	8.7	72
28	Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. *Breast Cancer Research and Treatment*, **1990**, 17, 59-61	4.4	21
27	Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. *Journal of Pathology*, **1990**, 162, 295-301	9.4	71
26	Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells. *The Histochemical Journal*, **1990**, 22, 498-506		30
25	Biology and natural history of breast cancer. *International Journal of Cancer*, **1990**, 5, 5-21	7.5	48
24	Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. *Cancer*, **1990**, 65, 1180-4	6.4	159
23	Analysis of DNA synthesis in herpes simplex virus infected cells by dual parameter flow cytometry. *Archives of Virology*, **1989**, 107, 215-23	2.6	5
22	Different opinions on classification of DNA histograms produced from paraffin-embedded tissue. *Cytometry*, **1989**, 10, 711-7		67
21	Flow cytometric DNA analysis of 199 histologically favourable or unfavourable non-Hodgkin lymphomas. *Journal of Pathology*, **1989**, 157, 27-36	9.4	44
20	Serum CA 125 in acute pelvic inflammatory disease. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1989**, 96, 574-9	3.7	21
19	Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **1989**, 32, 247-51	2.4	6
18	Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. *Clinical Immunology and Immunopathology*, **1989**, 52, 406-13		5

17	Prognostic assessment in stage I ovarian cancer using a discriminant analysis with clinicopathological and DNA flow cytometric data. *Gynecologic and Obstetric Investigation*, **1989**, 27, 213-6	2.5	10
16	Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. *Cancer*, **1989**, 63, 1761-7	6.4	72
15	Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. *Cancer*, **1988**, 61, 334-9	6.4	183
14	Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. *Cancer*, **1988**, 62, 2183-90	6.4	223
13	Elevated serum HMFG antigen levels in breast and ovarian cancer patients measured with a sandwich ELISA. *International Journal of Cancer*, **1988**, 2, 28-33	7.5	6
12	DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. *International Journal of Cancer*, **1988**, 42, 697-702	7.5	20
11	Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. *Cytometry*, **1988**, 9, 164-9		207
10	Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. *British Journal of Cancer*, **1988**, 58, 213-5	8.7	59
9	Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study. *Atherosclerosis*, **1988**, 69, 257-68	3.1	32
8	DNA ploidy level and cell cycle distribution in ovarian cancer: relation to histopathological features of the tumor. *International Journal of Gynecological Pathology*, **1988**, 7, 1-11	3.2	21
7	Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. *Tumor Biology*, **1988**, 9, 287-92	2.9	8
6	Nuclear DNA content of non-endemic Burkitt's lymphoma. *Journal of Clinical Pathology*, **1987**, 40, 1201-5	3.9	13
5	Tumour DNA ploidy as an independent prognostic factor in breast cancer. *British Journal of Cancer*, **1987**, 56, 637-42	8.7	152
4	Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. *European Journal of Cancer & Clinical Oncology*, **1987**, 23, 277-82		128
3	Growth properties and composition of cytoskeletal and cytocontractile proteins in aortic cells isolated and cultured from normal and atherosclerotic rabbits. *Atherosclerosis*, **1984**, 52, 13-26	3.1	13
2	Association of tamoxifen resistance and lipid reprogramming in breast cancer		1
1	FusionCatcher - a tool for finding somatic fusion genes in paired-end RNA-sequencing data		152